ArticleTherapeutic advances in medical oncology2025

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer.

Jiaming Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.